Cefpodoxime

**Antibiotic Class:**
Third-Generation Cephalosporin

**Antimicrobial Spectrum:**
*Staphylococcus aureus* (methicillin susceptible), Coagulase negative Staphylococci, *Streptococcus pneumoniae* (penicillin susceptible), *Streptococcus spp.*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Neisseria meningitides*, *Neisseria gonorrhoeae*, *Enterobacteriaceae*, *E. coli*

**Mechanism of Action:**
Cephalosporins exert bactericidal activity by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan. The cephalosporins are also thought to play a role in the activation of bacterial cell autolysins which may contribute to bacterial cell lysis.

**Pharmacodynamics:**
Cephalosporins exhibit time-dependent killing (T > MIC)

**Pharmacokinetics:**
Dose of 200mg: Cmax: 2.6 mcg/L; Tmax: 2.4 hour; Half-life: 2.3 hours; Table 10

**Adverse Effects:**
Hypersensitivity: Maculopapular rash, Urticaria, Pruritis, Anaphylaxis/angioedema, eosinophilia
Hematologic: Hypoprothrombinemia, Neutropenia, Leukopenia, Thrombocytopenia
GI: Diarrhea, *C. difficile* disease
Renal: Interstitial nephritis
Table 14

**Dosage:**
PO: 200mg, 400mg tablets
   Oral suspension: 50mg/5mL, 100mg/5mL

Dosing in adults:
Acute exacerbation of chronic bronchitis: 200 mg PO q 12h x 10 days
Lower respiratory tract infection: 200 mg PO q12h x 10 days
Acute maxillary sinusitis: 200 mg PO q12h x 10 days
UTI: 100 mg PO q12h x 7 days

Dosing in pediatrics:
10g/kg/day divided q12h

Disease state based dosing:
Renal failure: CrCl < 30 mL/min: increase dosing interval to every 24 hr
Hepatic failure: No dosing changes recommended at this time.
Contraindications/Warnings/Precautions:
Precautions: hypersensitivity to penicillins, history of gastrointestinal disease, particularly colitis, renal impairment

Drug Interactions:
Antacids: decreased cefpodoxime effectiveness
Calcium: decreased cefpodoxime effectiveness
H2 blockers: decreased cefpodoxime effectiveness
Live Typhoid Vaccine: decreased immunological response to the typhoid vaccine
Probenecid: increased serum cefpodoxime levels
Sodium Bicarbonate: decreased cefpodoxime effectiveness

Pregnancy:
Category B: No evidence of risk in humans but studies inadequate.

Monitoring Requirements:
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Toxic: Urinalysis, BUN, SCr, AST and ALT, skin rash, Neutropenia and leukopenia,
Prothrombin time in patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.

Brand names/Manufacturer: Vantin®/Pharmacid & Upjohn